转甲状腺素蛋白淀粉样心肌病中三尖瓣反流的预后阈值
该国际多中心队列研究纳入1124例新诊断ATTR-CM患者,通过盲法核心实验室定量分析三尖瓣反流参数,推导并验证疾病特异性预后阈值。结果显示新阈值框架较指南定义和TVARC分级更能预测全因死亡和心衰住院,支持ATTR-CM专用三尖瓣反流分级。
要点
- ATTR-CM中三尖瓣反流定量参数可独立预测全因死亡和心衰住院。
- 新阈值定义中危、高危和极高危,较指南定义识别更多高危患者。
- 新框架对死亡和心衰住院的区分能力优于现有指南分级。
核心结论
- 在ATTR-CM患者中,基于超声心动图参数的三尖瓣反流风险分层框架较标准分级更好地预测死亡和心衰住院。
研究设计与样本
- 国际多中心队列研究,2016年1月至2026年2月在奥地利、意大利、德国和荷兰8个高容量三级转诊中心开展。
- 共纳入1124例新诊断ATTR-CM患者,推导队列745例,验证队列379例。
- 中位年龄80岁,女性260例(23.1%),中位随访25.2个月。
主要发现
- 随访期间324例(28.8%)死亡,251例(22.3%)发生心衰住院。
- 所有三尖瓣反流指标均独立预测全因死亡和心衰住院两个终点。
- 样条推导阈值定义中危(VCW≥3 mm;EROA≥0.15 cm2;RegVol≥10 mL)、高危(≥5 mm;≥0.25 cm2;≥20 mL)和极高危(≥8 mm;≥0.50 cm2;≥40 mL)。
- 指南和TVARC方案各将130例(11.6%)归为重度三尖瓣反流,而新框架将334例(29.7%)归为至少高危或极高危(P < .001)。
- 新框架与两个终点独立相关,风险比最高(死亡:HR 1.41;95%CI 1.23-1.62;心衰住院:HR 1.31;95%CI 1.12-1.54)。
关键数值与推荐
- 中危阈值:VCW≥3 mm、EROA≥0.15 cm2、RegVol≥10 mL。
- 高危阈值:VCW≥5 mm、EROA≥0.25 cm2、RegVol≥20 mL。
- 极高危阈值:VCW≥8 mm、EROA≥0.50 cm2、RegVol≥40 mL。
临床怎么用
- 在ATTR-CM患者中采用疾病特异性三尖瓣反流定量阈值进行风险分层,可能比常规指南分级更准确识别高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In transthyretin amyloid cardiomyopathy (ATTR-CM), tricuspid regurgitation (TR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria derived from nonamyloid populations, given the restrictive, low-flow hemodynamics characteristic of the disease. OBJECTIVES: To derive and validate disease-specific prognostic, quantitative TR risk thresholds in ATTR-CM and to compare their prognostic performance with current guideline definitions and the Tricuspid Valve Academic Research Consortium (TVARC) 5-grade extension. DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter cohort study was conducted from January 2016 to February 2026 at 8 high-volume tertiary referral centers across Austria, Italy, Germany, and the Netherlands, with data analysis February to May 2026. Patients with newly diagnosed ATTR-CM were enrolled and underwent standardized transthoracic echocardiography with blinded core laboratory quantitative analysis of echocardiography TR severity parameters (vena contracta width [VCW], effective regurgitant orifice area [EROA], and regurgitant volume [RegVol]). EXPOSURES: TR severity defined by VCW, EROA, and RegVol from blinded core laboratory quantitative analysis and TR severity according to 2025 European Society of Cardiology/European Association for Cardio-Thoracic Surgery, 2020 American Heart Association/American College of Cardiology, 2017 American Society of Echocardiography, and 2023 TVARC grading schemes. MAIN OUTCOMES AND MEASURES: Outcomes were all-cause mortality (primary end point) and time to first heart failure hospitalization (HFH; secondary end point). RESULTS: A total of 1124 patients with newly diagnosed ATTR-CM were enrolled (derivation cohort: n = 745; validation cohort: n = 379). Median (IQR) patient age was 80 (75-84) years, and 260 patients (23.1%) were female. Over a median (IQR) follow-up of 25.2 (12.2-43.2) months, 324 patients (28.8%) died and 251 (22.3%) experienced HFH. All TR metrics independently predicted both end points. Spline-derived thresholds delineated intermediate (VCW ≥3 mm; EROA ≥0.15 cm2; RegVol ≥10 mL), high (≥5 mm; ≥0.25 cm2; ≥20 mL), and extreme risk (≥8 mm; ≥0.50 cm2; ≥40 mL), with stepwise Kaplan-Meier separation in both cohorts. Whereas the guideline-based and TVARC schemes each classified 130 patients (11.6%) as having severe TR, the proposed framework classified 334 patients (29.7%) as having at least high or extreme risk (P < .001 for comparison to all other definitions). The framework was independently associated with both end points, with the highest point estimate among the schemes (mortality: hazard ratio [HR], 1.41; 95% CI, 1.23-1.62; HFH: HR, 1.31; 95% CI, 1.12-1.54), and showed superior discrimination over guideline definitions, particularly at later time points. CONCLUSIONS AND RELEVANCE: In this multicenter cohort study among patients with ATTR-CM, a validated, risk-based conceptual framework of echocardiographic parameters to quantify TR improved prediction of mortality and HFH over standard classification of TR severity, better reflecting restrictive low-flow pathophysiology and supporting disease-specific TR grading in ATTR-CM.
引用
- Hauptmann L, Schwarting SK, Tomasoni D, et al. Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy. JAMA Cardiol. 2026. PMID: 42671012. doi:10.1001/jamacardio.2026.3803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。